What is HC Wainwright’s Estimate for HURA Q1 Earnings?

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for shares of TuHURA Biosciences in a report issued on Wednesday, August 19th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($0.15) for the quarter. The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for TuHURA Biosciences’ Q2 2027 earnings at ($0.15) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.61) EPS.

TuHURA Biosciences (NASDAQ:HURA) last announced its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01.

HURA has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citizens Jmp reissued a “market outperform” rating and set a $9.00 target price on shares of TuHURA Biosciences in a research report on Tuesday. Wall Street Zen lowered shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a research note on Sunday, May 31st. Finally, Citigroup started coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They issued an “outperform” rating on the stock. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $9.00.

TuHURA Biosciences Stock Performance

Shares of HURA opened at $2.28 on Thursday. The stock has a 50 day moving average of $2.29 and a 200 day moving average of $2.04. The company has a market capitalization of $145.30 million, a price-to-earnings ratio of -4.22 and a beta of -0.01. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $3.43. The company has a current ratio of 0.18, a quick ratio of 1.15 and a debt-to-equity ratio of 0.20.

Hedge Funds Weigh In On TuHURA Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Merck & Co. Inc. increased its stake in TuHURA Biosciences by 39.4% in the first quarter. Merck & Co. Inc. now owns 19,445 shares of the company’s stock valued at $35,000 after acquiring an additional 5,495 shares during the last quarter. PFG Investments LLC lifted its stake in TuHURA Biosciences by 39.4% during the first quarter. PFG Investments LLC now owns 32,630 shares of the company’s stock worth $58,000 after purchasing an additional 9,219 shares during the last quarter. Virtu Financial LLC bought a new stake in TuHURA Biosciences during the third quarter worth about $26,000. JPMorgan Chase & Co. purchased a new position in shares of TuHURA Biosciences in the 2nd quarter worth about $27,000. Finally, Invesco Ltd. purchased a new position in shares of TuHURA Biosciences in the 2nd quarter worth about $30,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.